The global capecitabine market has been steadily growing, and this trend is expected to continue in the coming years. The primary factor driving this growth is the rising prevalence of cancer worldwide. Cancer accounted for approximately 10 million deaths worldwide in 2020, with breast cancer, colorectal cancer, and liver cancer being among the most deadly. In response to this global health crisis, private and government organizations, such as Cancer Research UK and the American Cancer Society, have launched various cancer awareness programs.
Capecitabine is a chemotherapy medication that is used in the treatment of various types of cancer, including breast cancer, colorectal cancer, and gastric cancer. It is part of a group of drugs called antimetabolites, which are designed to inhibit the growth and proliferation of cancer cells. Capecitabine is most commonly sold under the brand name Xeloda and is administered orally. It was granted regulatory approval for medical use in 1998.
Request a sample Report of capecitabine market https://www.reportsanddata.com/download-free-sample/261
One of the primary drivers of the global capecitabine market is the growing use of the drug in the treatment of breast cancer. Capecitabine has been approved as an advanced medication for metastatic breast cancer, and studies have shown that it is effective and well-tolerated in breast cancer patients when used in combination with other chemotherapy agents, such as docetaxel and paclitaxel.
However, the growth of the capecitabine market is significantly hampered by the various side-effects associated with the drug. Some serious side-effects include anemia, chest pain, diarrhea, vomiting, weakness, blood clotting problems, and cardiac-related issues such as cardiomyopathy. Kidney disease, DPD deficiency, and pregnancy are among the other common contraindications of the drug.
The breast cancer segment is expected to account for the largest revenue share in the global capecitabine market over the forecast period. This is due to the rising prevalence of breast cancer, the increasing need for early cancer diagnosis, and ongoing R&D activities for breast cancer treatment. The North American market is expected to account for the largest revenue share, primarily due to the surging prevalence of different types of cancers, including breast cancer and colorectal cancer, in the region, rising prevalence of unhealthy lifestyle-induced diseases such as obesity and hypertension, rapid increase in the global geriatric population, and increasing government funding for cancer research.
Major companies operating in the global capecitabine market include Cipla Inc., Genentech, Inc., F. Hoffmann-La Roche, Ranbaxy Laboratories Ltd., Teva Pharma B.V., Mylan N.V., Sandoz, Fresenius SE & Co. KGaA, Zentiva N.V., Accord Healthcare Ltd., and Dr. Reddy Laboratories Ltd. In February 2021, Dr. Reddy’s Laboratories launched Capecitabine Tablets, USP, which is a therapeutic generic version of Xeloda Tablets, following approval by the U.S. FDA.
Mareket segmentation of capecitabine market
Indication Outlook (Revenue, USD Billion; 2018-2028)
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Others
Drug Type Outlook (Revenue, USD Billion; 2018-2028)
- Branded
- Generic
Drug Formulation Outlook (Revenue, USD Billion; 2018-2028)
- Tablets
- Capsules
End-use Outlook (Revenue, USD Billion; 2018-2028)
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)
- Hospital Pharmacies
- Retail Stores
- Online Pharmacies
- Others
Region Outlook (Revenue, USD Billion; 2018-2028)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Singapore
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
Request a customized copy of the report https://www.reportsanddata.com/request-customization-form/261
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
